Edition:
United States

Mayne Pharma Group Ltd (MYX.AX)

MYX.AX on Australia Stock Exchange

1.50AUD
5 Dec 2016
Change (% chg)

$-0.06 (-3.86%)
Prev Close
$1.55
Open
$1.55
Day's High
$1.56
Day's Low
$1.49
Volume
7,749,432
Avg. Vol
6,623,357
52-wk High
$2.11
52-wk Low
$1.06

MYX.AX

Chart for MYX.AX

About

Mayne Pharma Group Limited is a specialty pharmaceutical company, which focuses on applying its drug delivery capability to commercialize branded and generic pharmaceuticals. The Company also provides contract development and manufacturing services. It operates in four segments: Generic Products (GPD), Specialty Brands (SBD),... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $2,290.21
Shares Outstanding(Mil.): 1,491.99
Dividend: --
Yield (%): --

Financials

  MYX.AX Industry Sector
P/E (TTM): 35.25 29.13 29.87
EPS (TTM): 0.04 -- --
ROI: 7.57 15.56 14.95
ROE: 11.07 16.69 16.29

BRIEF-Mayne Pharma Group updates on legal proceedings

* Continues to believe these investigations will not have a material impact on its future earnings

Nov 03 2016

BRIEF-IDT Australia ships first Generic Temozolomide Capsules to USA

* Shipped first of its new proprietary generic pharmaceutical products to its us distribution partner, Mayne Pharma Group Source text for Eikon: Further company coverage:

Nov 01 2016

BRIEF-Mayne Pharma launches Budesonide capsules in United States

* Mayne Pharma launches budesonide capsules in us Source text for Eikon: Further company coverage:

Oct 26 2016

Teva, Allergan win U.S. antitrust approval for generics deal

WASHINGTON Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.

Jul 27 2016

UPDATE 2-Teva, Allergan win U.S. antitrust approval for generics deal

WASHINGTON, July 27 Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.

Jul 27 2016

Mayne Pharma nears deal for Teva assets: source

Australia's Mayne Pharma Group Ltd on Tuesday said it will acquire U.S. generic products from Teva Pharmaceuticals for $652 million, helping it propel into the top 2 in the general oral contraceptives market in the United States.

Jun 27 2016

Earnings vs. Estimates